|
|
|
Insider
Information: |
Altshuler David |
Relationship: |
EVP, Chief Scientific... |
City: |
Cambridge |
State: |
MA |
|
|
Insider
Summary: |
|
|
|
Companies Owned : |
1 |
|
Direct
Shares |
25,813 |
|
Indirect Shares
|
0 |
|
|
Direct
Value |
$11,436,450 |
|
|
Indirect Value
|
$0 |
|
|
Total
Shares |
25,813 |
|
|
Total
Value |
$11,436,450 |
|
|
|
|
|
|
|
|
Historical
Performance :
Based on 6 Month Return Percentages |
Buys
|
Sells
|
Total
Filings :
|
0
|
0
|
Stock
price went up :
|
0
|
0
|
Stock
price went down : |
0
|
0
|
|
|
|
Gain/Loss Ratio : |
0.0
|
0.0
|
Percentage
Gain/Loss : |
0.0%
|
0.0%
|
|
|
|
|
|
|
Holdings
:
Menu |
Company Name |
Ticker |
Relation |
Direct Date |
Direct Shares |
Indirect Date |
Indirect Shares |
Total Value Sold |
|
Vertex Pharmaceuticals Inc |
VRTX |
EVP, Chief Scientific... |
2024-05-15 |
25,813 |
2014-07-31 |
0 |
Premium* |
|
|
|
|
|
|
|
|
|
|
Records found :
157 |
Free Registration Required For Full Results. Limit: 25
|
|
Download |
Page 2 of 7
|
Ticker |
Company Name |
Relation |
Off-Dir-10% |
Trans. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
3m +/- |
|
|
Form |
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-02-13 |
4 |
AS |
$87.68 |
$561,415 |
D/D |
(6,403) |
106,011 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-04-28 |
4 |
AS |
$120.00 |
$900,000 |
D/D |
(7,500) |
106,011 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-04-28 |
4 |
OE |
$63.14 |
$473,550 |
D/D |
7,500 |
113,511 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-05-15 |
4 |
AS |
$114.37 |
$20,701 |
D/D |
(181) |
106,011 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-06-05 |
4 |
OE |
$72.14 |
$541,050 |
D/D |
7,500 |
113,511 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-06-05 |
4 |
AS |
$130.00 |
$975,000 |
D/D |
(7,500) |
106,011 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-07-19 |
4 |
AS |
$161.00 |
$4,665,619 |
D/D |
(28,979) |
106,011 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-07-19 |
4 |
OE |
$81.54 |
$2,448,338 |
D/D |
28,979 |
134,990 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-08-31 |
4 |
AS |
$160.00 |
$287,360 |
D/D |
(1,796) |
106,011 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-08-31 |
4 |
OE |
$91.05 |
$163,526 |
D/D |
1,796 |
107,807 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2017-11-15 |
4 |
AS |
$147.71 |
$45,630 |
D/D |
(306) |
106,011 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-01-16 |
4 |
AS |
$155.77 |
$8,830,755 |
D/D |
(56,250) |
49,761 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-01-22 |
4 |
AS |
$160.00 |
$287,360 |
D/D |
(1,796) |
49,761 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-01-22 |
4 |
OE |
$91.05 |
$163,526 |
D/D |
1,796 |
51,557 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-02-02 |
4 |
AS |
$165.24 |
$298,330 |
D/D |
(1,796) |
49,761 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-02-02 |
4 |
OE |
$91.05 |
$163,526 |
D/D |
1,796 |
51,557 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-02-06 |
4 |
A |
$0.00 |
$0 |
D/D |
26,641 |
76,402 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-02-12 |
4 |
AS |
$149.23 |
$965,671 |
D/D |
(6,403) |
69,999 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-05-15 |
4 |
AS |
$155.78 |
$15,266 |
D/D |
(98) |
69,999 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-06-29 |
4 |
AS |
$161.57 |
$7,313,596 |
D/D |
(44,331) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-06-29 |
4 |
OE |
$86.52 |
$1,171,397 |
D/D |
13,445 |
83,444 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-07-16 |
4 |
AS |
$182.00 |
$4,254,250 |
D/D |
(23,375) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-07-16 |
4 |
OE |
$131.89 |
$3,082,929 |
D/D |
23,375 |
62,488 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-08-02 |
4 |
AS |
$174.59 |
$313,564 |
D/D |
(1,796) |
39,113 |
0 |
- |
|
VRTX |
Vertex Pharmaceuticals In... |
EVP, Global Research and CSO |
|
2018-08-02 |
4 |
OE |
$91.05 |
$163,526 |
D/D |
1,796 |
40,909 |
0 |
- |
|
157 Records found
|
|
Page 2 of 7 |
|
Free Registration Required For Full Results. Limit: 25
|
|
|
Transaction Code Key: |
Ownership Code Key |
|
B |
- Buy |
AB |
- Automatic Buy |
D |
- Direct Ownership |
|
S |
- Sell |
AS |
- Automatic Sell |
I |
- Indirect Ownership |
|
OE |
- Options Exercised |
A |
- Aquired |
|
IO |
- Initital Ownership |
D |
- Disposed |
|
|
|
|
|
|